Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

signalling pathways 2013 banner
Start date
01 Mar 2013
End date
02 Mar 2013
Sitges, Spain

Targeting the HER/EGFR family: Focus on breast, lung and colorectal cancers

The goal was to educate participants on state of the art research and science behind targeting EGFR/HER family in three most frequent cancer types. The Symposium hosted approximately 200 attendees in order to allow maximum interactions with faculty. A plenary discussion on principles of signalling transduction, mechanisms of primary and secondary resistance to targeted therapy, preclinical models and biomarkers dissection, was implemented by discussion within parallel sessions on dysregulation of HER receptors and subsequent potentials for targeting by different strategies in breast, lung and colorectal cancers. Additional panel expert discussion brought synthesis on different aspects elaborated during the presentations and confronted the complexity of current challenges in the field with intention to provide a future perspective for innovative collaborations between academia and pharma.

Download the Programme Book

Signalling Pathways 2013 Scientific Manuscript

Read the editorial article on ESMO first signalling pathways symposium and personalised cancer medicine published by Prof. Martine Piccart in the August 2013 issue of Annals of Oncology.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.